May 11, 2018 – In a recent Drug Channels blog post, Adam Fein reports that 340B spending has reached $19.3 billion in 2017, and claims that 340B is “a significant and growing part of the [pharmaceutical] industry.” However, that conclusion is not supported by the facts. In fact, Fein’s own numbers suggest a different narrative regarding the size and impact of the 340B program … [Read more...]
What Does President Trump’s Drug Pricing Plan Mean for 340B?
May 11, 2018—While the 340B drug pricing program played a minor supporting role in President Trump’s drug pricing announcements today, it is certain to engender significant debate in the months ahead. The announcements made today no new policy proposals but did continue rhetorical attacks on the program. The President never uttered the words “340B” but did reference the … [Read more...]
Hospitals’ Lawsuit Over Medicare’s Deep 340B Cuts Has Court Hearing
May 7, 2018—Federal appeals court judges in Washington focused largely on procedural issues during a May 4 hearing over a nearly 30 percent cut in Medicare drug payments to certain 340B hospitals. A lawsuit by hospital groups and health systems over the cut was the subject of oral arguments before a three-judge panel of the U.S. Court of Appeals for the District of Columbia … [Read more...]
Faces of 340B: Healthy Kids, Healthy Adults
May 2, 2018—Children make up one of the key groups of people who are helped by the 340B drug pricing program. At JPS Health Network in Fort Worth, Texas, a commitment to use 340B to benefit some of the health system’s youngest patients is on full display. JPS is the safety net hospital system for Tarrant County. Using the $50 million in savings that it gets through the 340B … [Read more...]
Drug Prices Continue to Soar and the Public Notices
March 27, 2018—A trio of new reports out this past week indicates that the historic rise in prescription drug prices in the U.S. continues and the American public is concerned. First, a report by Axios found the prices of the top 20 drugs prescribed in the U.S. rose by more than 200 percent in the past 14 months. Based on an analysis by Pharmacy Benefits Consultants, Axios … [Read more...]
Faces of 340B: “I Just Started Crying”
March 20, 2018—For Kathleen Cavanagh of Caldwell, Idaho, finding the 340B program was a momentous event that she describes as a “happy accident.” With a host of serious medical conditions, including type 1 diabetes, asthma, high blood pressure, and bipolar disorder, Kathleen was reliant on various prescription assistance programs to help pay the high costs of her many … [Read more...]
PhRMA-Funded Study Contradicts Its Conclusions
March 19, 2018 – A new PhRMA-funded study released by Milliman suggests that 340B hospitals have higher drug spending for commercially insured patients than non-340B hospitals and claims that it is the result of inappropriate drug use. However, methodological flaws in the study raise serious questions about the findings. In fact, Milliman’s report includes data that indicate … [Read more...]